Furthermore, studies from a large randomized cardiovascular safety trial and an extended analysis of phase 3b/4 safety data demonstrated a higher incidence of major adverse cardiovascular events and cancer in patients with rheumatoid arthritis receiving tofacitinib compared to anti-TNF [10,11]. The gene discussed is TNF; the disease is rheumatoid arthritis.